Highlights

  • BCAL Diagnostics shares fell 10.35% to AUD 0.052 during the session.
  • BCAL recently secured additional funding to support its FY27 activities.
  • BREASTEST Monitor returned initial sensitivity of 91% in women aged 50 and above.
  • The company is progressing US validation of BREASTESTplus Version 2 with Sonic Healthcare USA.

BCAL Diagnostics Ltd (ASX:BDX) is moving into FY27 with additional funding and a growing portfolio of blood-based cancer detection products.

BCAL shares were trading at AUD 0.052, down 10.35%, with a Market Capitalisation of approximately AUD 19.17 million.

Recent developments span funding, product development and commercial access.

Funding Supports FY27 Program

BCAL announced another funding update on 21 August as it continues financing its FY27 work program.

During the June quarter, the company had already secured AUD 4.9 million under its existing convertible note Facility and AUD 1.4 million as a first Tranche against its FY26 R&D tax offset.

For an emerging diagnostics company, that capital provides support for product validation, commercial rollout and regulatory work.

Cancer Test Portfolio Continues to Expand

BCAL’s June quarter included development of BREASTEST Monitor, which is being evaluated for local breast cancer recurrence.

Initial findings showed sensitivity of 91% and a negative predictive value of 95% in women aged 50 years and above.

The company also entered an agreement with Sonic Healthcare USA to validate BREASTESTplus Version 2 in the United States.

Meanwhile, its commercial infrastructure in Australia has expanded through referral pathways designed to make its early-detection tests accessible to a wider network of clinicians.

Earlier in 2026, BCAL accelerated national availability of its Avantect Pancreatic and Ovarian tests through selected Sonic Healthcare centres and the Healius Pathology Network.

What Could Drive BCAL Shares Next?

Clinical validation data, testing volumes and progress in the United States could become increasingly important as BCAL moves from product development towards broader commercial utilisation.

Reimbursement pathways and further financing developments also remain relevant.

BCAL Diagnostics Outlook

BCAL enters FY27 with additional funding, expanding Australian test access and multiple validation programs. Progress with BREASTESTplus, BREASTEST Monitor and its Avantect portfolio will help determine how quickly the company can broaden commercial adoption.